What does it take to build a true “backbone” cancer therapy? In a recent conversation, Dan Schmitt, CEO of...
Read more
Actuate Therapeutics announced the publication of positive Phase II clinical data from a study evaluating elraglusib in combination with platinum...
Read more
Actuate Therapeutics has submitted an updated clinical data package to the FDA to support upcoming regulatory discussions with both...
Read more
Actuate Therapeutics has launched an exciting new Phase 1b clinical trial in collaboration with Incyte Corporation and the University of...
Read more
Actuate Therapeutics, Inc. has achieved extraordinary results in its Phase 1 study of elraglusib in pediatric patients with refractory Ewing...
Read more
Actuate Therapeutics, Inc. (ACTU) announced hat the Company will be added to the Russell 3000® Index, with automatic inclusion...
Read more
Actuate Therapeutics (NASDAQ: ACTU) has announced positive Phase 2 trial results for elraglusib in treating metastatic pancreatic ductal adenocarcinoma...
Read more
Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at...
Read more
Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat...
Read more
Actuate Therapeutics, Inc. announced the completion of patient enrollment in the ongoing Phase 2 trial of FOLFIRINOX in combination...
Read more